Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Altimmune (ALT) Income towards Parent Company: 2010-2024

Historic Income towards Parent Company for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to -$95.1 million.

  • Altimmune's Income towards Parent Company rose 16.77% to -$19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$84.0 million, marking a year-over-year increase of 18.82%. This contributed to the annual value of -$95.1 million for FY2024, which is 7.53% down from last year.
  • According to the latest figures from FY2024, Altimmune's Income towards Parent Company is -$95.1 million, which was down 7.53% from -$88.4 million recorded in FY2023.
  • Over the past 5 years, Altimmune's Income towards Parent Company peaked at -$49.0 million during FY2020, and registered a low of -$97.1 million during FY2021.
  • For the 3-year period, Altimmune's Income towards Parent Company averaged around -$89.4 million, with its median value being -$88.4 million (2023).
  • As far as peak fluctuations go, Altimmune's Income towards Parent Company tumbled by 139.01% in 2020, and later rose by 12.75% in 2022.
  • Over the past 5 years, Altimmune's Income towards Parent Company (Yearly) stood at -$49.0 million in 2020, then slumped by 97.96% to -$97.1 million in 2021, then rose by 12.75% to -$84.7 million in 2022, then fell by 4.41% to -$88.4 million in 2023, then decreased by 7.53% to -$95.1 million in 2024.